Resistance to Arsenic Therapy in Acute Promyelocytic Leukemia
Although resistance to arsenic trioxide in patients with acute promyelocytic leukemia is very rare, mutations in PML at the site of arsenic binding appears to be the main mechanism of resistance. To the Editor: Acute promyelocytic leukemia (APL) is a highly curable disease. Recently, two randomized...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2014-05, Vol.370 (19), p.1864-1866 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1866 |
|---|---|
| container_issue | 19 |
| container_start_page | 1864 |
| container_title | The New England journal of medicine |
| container_volume | 370 |
| creator | Zhu, Hong-Hu Qin, Ya-Zhen Huang, Xiao-Jun |
| description | Although resistance to arsenic trioxide in patients with acute promyelocytic leukemia is very rare, mutations in
PML
at the site of arsenic binding appears to be the main mechanism of resistance.
To the Editor:
Acute promyelocytic leukemia (APL) is a highly curable disease. Recently, two randomized trials conducted by Lo-Coco et al.
1
and our group
2
provided strong evidence supporting front-line treatment with arsenic trioxide and all-
trans
retinoic acid (ATRA) for APL. This treatment has been adopted by the most recent National Comprehensive Cancer Network guidelines.
1
The direct-binding targets of arsenic trioxide in the promyelocytic leukemia protein (PML) B2 domain are required to induce a molecular response in APL.
3
,
4
Mutant PML-C212/213 has been shown to lead to resistance to arsenic trioxide in an ex vivo model, but this association has . . . |
| doi_str_mv | 10.1056/NEJMc1316382 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1523401415</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3298233821</sourcerecordid><originalsourceid>FETCH-LOGICAL-c452t-e7d39b4d77f2c2a2582dfabc864a03d09f668b9c63dc20d580d35c10a10dc0b23</originalsourceid><addsrcrecordid>eNpt0DtPwzAUBWALgWgpbMwoEgwMBK6fcQaGqiovlYdQmSPHdkRKnRQ7GfLvSdWCEOIuHu6nI9-D0DGGSwxcXD1NHx41plhQSXbQEHNKY8ZA7KIhAJExS1I6QAchLKAfzNJ9NCBMgsCSD9H1qw1laFSlbdTU0dgHW5U6mr9br1ZdVFbRWLeNjV587Tq7rHXX9OuZbT-sK9Uh2ivUMtij7TtCbzfT-eQunj3f3k_Gs1gzTprYJoamOTNJUhBNFOGSmELlWgqmgBpICyFknmpBjSZguARDucagMBgNOaEjdL7JXfn6s7WhyVwZtF0uVWXrNmSYE8r62_rjR-j0D13Ura_6360VSTgklPXqYqO0r0PwtshWvnTKdxmGbF1r9rvWnp9sQ9vcWfODv3vswdkGOBeyyi7c_zlfBUd7kg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1522750734</pqid></control><display><type>article</type><title>Resistance to Arsenic Therapy in Acute Promyelocytic Leukemia</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>ProQuest Central UK/Ireland</source><source>New England Journal of Medicine</source><creator>Zhu, Hong-Hu ; Qin, Ya-Zhen ; Huang, Xiao-Jun</creator><creatorcontrib>Zhu, Hong-Hu ; Qin, Ya-Zhen ; Huang, Xiao-Jun</creatorcontrib><description>Although resistance to arsenic trioxide in patients with acute promyelocytic leukemia is very rare, mutations in
PML
at the site of arsenic binding appears to be the main mechanism of resistance.
To the Editor:
Acute promyelocytic leukemia (APL) is a highly curable disease. Recently, two randomized trials conducted by Lo-Coco et al.
1
and our group
2
provided strong evidence supporting front-line treatment with arsenic trioxide and all-
trans
retinoic acid (ATRA) for APL. This treatment has been adopted by the most recent National Comprehensive Cancer Network guidelines.
1
The direct-binding targets of arsenic trioxide in the promyelocytic leukemia protein (PML) B2 domain are required to induce a molecular response in APL.
3
,
4
Mutant PML-C212/213 has been shown to lead to resistance to arsenic trioxide in an ex vivo model, but this association has . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMc1316382</identifier><identifier>PMID: 24806185</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Acute promyeloid leukemia ; Arsenic ; Arsenic trioxide ; Arsenicals - therapeutic use ; Chemotherapy ; Drug Resistance, Neoplasm - genetics ; Humans ; Leukemia ; Leukemia, Promyelocytic, Acute - drug therapy ; Leukemia, Promyelocytic, Acute - genetics ; Mutation ; Neoplasm Proteins - genetics ; Oxides - therapeutic use ; Promyeloid leukemia ; Receptors, Retinoic Acid - genetics ; Retinoic Acid Receptor alpha</subject><ispartof>The New England journal of medicine, 2014-05, Vol.370 (19), p.1864-1866</ispartof><rights>Copyright © 2014 Massachusetts Medical Society. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c452t-e7d39b4d77f2c2a2582dfabc864a03d09f668b9c63dc20d580d35c10a10dc0b23</citedby><cites>FETCH-LOGICAL-c452t-e7d39b4d77f2c2a2582dfabc864a03d09f668b9c63dc20d580d35c10a10dc0b23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMc1316382$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1522750734?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,2759,2760,26103,27924,27925,52382,54064,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24806185$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhu, Hong-Hu</creatorcontrib><creatorcontrib>Qin, Ya-Zhen</creatorcontrib><creatorcontrib>Huang, Xiao-Jun</creatorcontrib><title>Resistance to Arsenic Therapy in Acute Promyelocytic Leukemia</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>Although resistance to arsenic trioxide in patients with acute promyelocytic leukemia is very rare, mutations in
PML
at the site of arsenic binding appears to be the main mechanism of resistance.
To the Editor:
Acute promyelocytic leukemia (APL) is a highly curable disease. Recently, two randomized trials conducted by Lo-Coco et al.
1
and our group
2
provided strong evidence supporting front-line treatment with arsenic trioxide and all-
trans
retinoic acid (ATRA) for APL. This treatment has been adopted by the most recent National Comprehensive Cancer Network guidelines.
1
The direct-binding targets of arsenic trioxide in the promyelocytic leukemia protein (PML) B2 domain are required to induce a molecular response in APL.
3
,
4
Mutant PML-C212/213 has been shown to lead to resistance to arsenic trioxide in an ex vivo model, but this association has . . .</description><subject>Acute promyeloid leukemia</subject><subject>Arsenic</subject><subject>Arsenic trioxide</subject><subject>Arsenicals - therapeutic use</subject><subject>Chemotherapy</subject><subject>Drug Resistance, Neoplasm - genetics</subject><subject>Humans</subject><subject>Leukemia</subject><subject>Leukemia, Promyelocytic, Acute - drug therapy</subject><subject>Leukemia, Promyelocytic, Acute - genetics</subject><subject>Mutation</subject><subject>Neoplasm Proteins - genetics</subject><subject>Oxides - therapeutic use</subject><subject>Promyeloid leukemia</subject><subject>Receptors, Retinoic Acid - genetics</subject><subject>Retinoic Acid Receptor alpha</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpt0DtPwzAUBWALgWgpbMwoEgwMBK6fcQaGqiovlYdQmSPHdkRKnRQ7GfLvSdWCEOIuHu6nI9-D0DGGSwxcXD1NHx41plhQSXbQEHNKY8ZA7KIhAJExS1I6QAchLKAfzNJ9NCBMgsCSD9H1qw1laFSlbdTU0dgHW5U6mr9br1ZdVFbRWLeNjV587Tq7rHXX9OuZbT-sK9Uh2ivUMtij7TtCbzfT-eQunj3f3k_Gs1gzTprYJoamOTNJUhBNFOGSmELlWgqmgBpICyFknmpBjSZguARDucagMBgNOaEjdL7JXfn6s7WhyVwZtF0uVWXrNmSYE8r62_rjR-j0D13Ura_6360VSTgklPXqYqO0r0PwtshWvnTKdxmGbF1r9rvWnp9sQ9vcWfODv3vswdkGOBeyyi7c_zlfBUd7kg</recordid><startdate>20140508</startdate><enddate>20140508</enddate><creator>Zhu, Hong-Hu</creator><creator>Qin, Ya-Zhen</creator><creator>Huang, Xiao-Jun</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20140508</creationdate><title>Resistance to Arsenic Therapy in Acute Promyelocytic Leukemia</title><author>Zhu, Hong-Hu ; Qin, Ya-Zhen ; Huang, Xiao-Jun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c452t-e7d39b4d77f2c2a2582dfabc864a03d09f668b9c63dc20d580d35c10a10dc0b23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Acute promyeloid leukemia</topic><topic>Arsenic</topic><topic>Arsenic trioxide</topic><topic>Arsenicals - therapeutic use</topic><topic>Chemotherapy</topic><topic>Drug Resistance, Neoplasm - genetics</topic><topic>Humans</topic><topic>Leukemia</topic><topic>Leukemia, Promyelocytic, Acute - drug therapy</topic><topic>Leukemia, Promyelocytic, Acute - genetics</topic><topic>Mutation</topic><topic>Neoplasm Proteins - genetics</topic><topic>Oxides - therapeutic use</topic><topic>Promyeloid leukemia</topic><topic>Receptors, Retinoic Acid - genetics</topic><topic>Retinoic Acid Receptor alpha</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhu, Hong-Hu</creatorcontrib><creatorcontrib>Qin, Ya-Zhen</creatorcontrib><creatorcontrib>Huang, Xiao-Jun</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhu, Hong-Hu</au><au>Qin, Ya-Zhen</au><au>Huang, Xiao-Jun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Resistance to Arsenic Therapy in Acute Promyelocytic Leukemia</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2014-05-08</date><risdate>2014</risdate><volume>370</volume><issue>19</issue><spage>1864</spage><epage>1866</epage><pages>1864-1866</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>Although resistance to arsenic trioxide in patients with acute promyelocytic leukemia is very rare, mutations in
PML
at the site of arsenic binding appears to be the main mechanism of resistance.
To the Editor:
Acute promyelocytic leukemia (APL) is a highly curable disease. Recently, two randomized trials conducted by Lo-Coco et al.
1
and our group
2
provided strong evidence supporting front-line treatment with arsenic trioxide and all-
trans
retinoic acid (ATRA) for APL. This treatment has been adopted by the most recent National Comprehensive Cancer Network guidelines.
1
The direct-binding targets of arsenic trioxide in the promyelocytic leukemia protein (PML) B2 domain are required to induce a molecular response in APL.
3
,
4
Mutant PML-C212/213 has been shown to lead to resistance to arsenic trioxide in an ex vivo model, but this association has . . .</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>24806185</pmid><doi>10.1056/NEJMc1316382</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2014-05, Vol.370 (19), p.1864-1866 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1523401415 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; ProQuest Central UK/Ireland; New England Journal of Medicine |
| subjects | Acute promyeloid leukemia Arsenic Arsenic trioxide Arsenicals - therapeutic use Chemotherapy Drug Resistance, Neoplasm - genetics Humans Leukemia Leukemia, Promyelocytic, Acute - drug therapy Leukemia, Promyelocytic, Acute - genetics Mutation Neoplasm Proteins - genetics Oxides - therapeutic use Promyeloid leukemia Receptors, Retinoic Acid - genetics Retinoic Acid Receptor alpha |
| title | Resistance to Arsenic Therapy in Acute Promyelocytic Leukemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T08%3A05%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Resistance%20to%20Arsenic%20Therapy%20in%20Acute%20Promyelocytic%20Leukemia&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Zhu,%20Hong-Hu&rft.date=2014-05-08&rft.volume=370&rft.issue=19&rft.spage=1864&rft.epage=1866&rft.pages=1864-1866&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMc1316382&rft_dat=%3Cproquest_cross%3E3298233821%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1522750734&rft_id=info:pmid/24806185&rfr_iscdi=true |